Actuate Therapeutics Inc
Support and Resistance Levels
Past performance
News About ACTU
All events for ACTU
All deals for ACTU
Financial Ratios
Financial Statements
ACTU vs Sector & Peers
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas. Website actuatetherapeutics.com
Headquarters Fort Worth, TX, US